Analyzing Seres Therapeutics (NASDAQ:MCRB) and NuCana (NASDAQ:NCNA)

NuCana (NASDAQ:NCNA) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.

Institutional and Insider Ownership

44.0% of NuCana shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 31.2% of NuCana shares are owned by company insiders. Comparatively, 5.2% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

NuCana has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for NuCana and Seres Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1	0	0	0	1.00
Seres Therapeutics	1	1	2	0	2.25

Seres Therapeutics has a consensus target price of $17.00, indicating a potential upside of 218.95%. Given Seres Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Seres Therapeutics is more favorable than NuCana.

Profitability

This table compares NuCana and Seres Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-153.61%	-116.03%
Seres Therapeutics	N/A	-130.29%	-35.35%

Earnings & Valuation

This table compares NuCana and Seres Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71 million	($2.98)	-0.44
Seres Therapeutics	$1.15 million	45.00	$5.70 million	($5.17)	-1.03

Seres Therapeutics has higher revenue and earnings than NuCana. Seres Therapeutics is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Summary

Seres Therapeutics beats NuCana on 8 of the 12 factors compared between the two stocks.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

About Seres Therapeutics

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company’s lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn’s disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.